Minerva Surgical

UTRS62

High Growth

$0.010.00%$0.00

High Growth

Penny Stock

UTRS62

$0.01

0.00%$0.00

High Growth

Penny Stock

Performance History

Key Stats
Open	$0.01
Prev. Close	$0.01
EPS	-7.61
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$106.54K
PE Ratio	-

	LOW	HIGH
Day Range	0.01	0.01
52 Week Range	0.00	6.16

Ratios

Revenue	-





EPS	-7.61

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Minerva Surgical (UTRS)

Minerva Surgical, Inc. (UTRS) is a medical technology company specialized in providing innovative solutions for the treatment of women's health conditions. The company focuses on developing minimally invasive devices that offer safe and effective options to improve patient outcomes. With a commitment to advancing the field of gynecology, Minerva Surgical has gained recognition for its groundbreaking technologies and products.

One of the key offerings from Minerva Surgical is the innovative product known as the Minerva Endometrial Ablation System. This system is designed to treat abnormal uterine bleeding, a common condition affecting many women. The Minerva Endometrial Ablation System provides a quick and effective procedure that can be performed in the convenience of an office setting, minimizing the need for complex surgeries. This device has been clinically proven to provide significant improvement in patient symptoms and quality of life.

Websitecall_made

Sector: Healthcare
Industry: Health Information Services
CEO: Mr. Todd Usen
Headquarters: Santa Clara
Employees: 174
Exchange: NASDAQ

Keep an eye on Minerva Surgical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Minerva Surgical's (UTRS) price per share?

The current price per share for Minerva Surgical (UTRS) is $0.01. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Minerva Surgical (UTRS)?

For Minerva Surgical (UTRS), the 52-week high is $6.16, which is 51.23K% from the current price. The 52-week low is $0, the current price is 1.1K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Minerva Surgical (UTRS) a growth stock?

Minerva Surgical (UTRS) has shown an average price growth of -6.65% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Minerva Surgical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Minerva Surgical (UTRS) stock price performance year to date (YTD)?

As of the latest data, Minerva Surgical (UTRS) has a year-to-date price change of -98.82%.

help

Is Minerva Surgical (UTRS) a profitable company?

Minerva Surgical (UTRS) has a net income of -$33.45M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 54.18% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -50.95% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 2.78%, providing insight into the company's sales performance and growth. The gross profit is $28.01M. Operating income is noted at -$29.26M. Furthermore, the EBITDA is -$25.56M.

help

What is the market capitalization of Minerva Surgical (UTRS)?

Minerva Surgical (UTRS) has a market capitalization of $106.54K. The average daily trading volume is 0, indicating the stock's liquidity and investor engagement.